Restarting Wegovy After a Two-Week Break: What the Guidance Says

What the Wegovy SmPC and NHS guidance actually say about dose gaps

The Wegovy Summary of Product Characteristics, available on the electronic Medicines Compendium, sets out the licensed escalation schedule: 0.25 mg for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each step separated by at least four weeks. That schedule exists precisely because tolerability is built incrementally. The SmPC also notes that if a dose is missed, it can be taken within five days; beyond that, the missed dose should be skipped and the next injection taken on the usual day. Two weeks means two consecutive missed doses, and the prescribing information and NHS patient guidance on semaglutide are clear that a gap of this scale warrants clinical review before continuing.

Semaglutide has a half-life of roughly seven days. After a fortnight, plasma concentrations have declined significantly from the steady state your body had reached. Reintroducing the medicine at your previous maintenance dose treats your system as though that steady state still exists, which it doesn't. The practical consequence is a higher likelihood of the gastrointestinal side effects (nausea, vomiting, loose stools, reflux) that the slow titration schedule is designed to prevent.

None of this means restarting is complicated. It means restarting needs a prescriber's input rather than a self-directed decision. The specific dose you go back to, and whether you need to step down by one or two levels, depends on factors your prescriber will weigh: how long you'd been stable at your previous dose, your side-effect history, and why the gap happened.

Why the length of time you'd been on your previous dose matters

There is a meaningful difference between someone who had been on 2.4 mg for six months before a two-week break and someone who had only just reached that dose the week before they stopped. Longer stability at a given dose suggests a more established tolerance, which some prescribers factor into the restart conversation. That said, the SmPC does not make this distinction formally, it is a clinical judgement call, not a fixed formula.

If you had been stable on a maintenance dose for several months and the break was unavoidable (illness, supply issue, travel), your prescriber may consider restarting one step below your previous dose rather than returning to 0.25 mg. If the break followed side effects, or you had only recently reached a higher dose, a more cautious step-down is likely. There is also a separate question about how a longer gap (say, a month or more) would change the picture, since the guidance becomes progressively more conservative the longer the treatment has been paused.

The NICE technology appraisal for semaglutide (Wegovy), TA875, frames treatment in the context of ongoing clinical oversight within a specialist weight management pathway. That framing reinforces what the SmPC says at the level of individual dose decisions: these are choices made with a clinician, not independently.

Side effects to watch for when you restart, and when to get medical help

The most common side effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion and burping. After a break, these are more likely to resurface on the early injections, particularly if you restart at a dose your body hasn't recently been exposed to. They typically settle within a week or two as your system readjusts, and eating smaller meals, avoiding fatty or spicy foods, and staying well hydrated tend to help during that period.

There are some symptoms that require urgent medical attention rather than watchful waiting. Severe, persistent abdominal pain that radiates to the back (with or without vomiting) can be a sign of pancreatitis, which the MHRA highlighted as a known but uncommon risk in a Drug Safety Update issued in January 2026. Seek same-day medical help if that pattern appears. Signs of gallbladder problems (sharp pain in the upper right abdomen, fever, jaundice), or any signs of an allergic reaction, also need prompt assessment. Suspected side effects can be reported via the MHRA's Yellow Card scheme.

If you're managing your Wegovy prescription through a GPhC-registered online pharmacy, your prescriber should be your first call when planning to restart after any gap, not just because of the dose question, but because aftercare support is part of what a regulated service provides. Our FAQs cover what to expect from the review process if you've had a treatment break.

How to get a clinical restart assessment

The practical path is straightforward. Contact the prescriber or pharmacy managing your treatment, explain that you've had a two-week gap, and ask for a clinical review before your next dose. A good prescriber will want to know why the gap happened, what dose you were on, and whether you experienced any side effects beforehand. That conversation takes minutes and removes the guesswork entirely.

If you are new to Wegovy or looking at treatment options more broadly, our treatment overview page explains how private prescribing works and what the eligibility criteria look like. For context on how a longer break would affect the restart picture, the guidance for gaps of six weeks or more goes into more detail on what progressive dose reduction typically involves. If your gap has stretched to around four weeks, you can find specific clinical considerations on the page covering what to do when restarting Wegovy after four weeks. And if your situation involves a break closer to three weeks, the considerations are similar to those discussed here, you can read the full breakdown on the three-week restart page.

For those who have been off treatment for considerably longer, our guidance on restarting Wegovy after two months explains how the restart approach changes when the gap extends well beyond a few weeks.

Speak to our prescribers if you'd like a clinical assessment of where to restart and what to expect. Consultations are free, reviewed by a GPhC-registered Independent Prescriber, and available seven days a week for aftercare questions.